Skip to main content

Articles

Page 2 of 36

  1. Acute myeloid leukemia (AML) is an aggressive blood cancer with poor clinical outcomes. Emerging data suggest that mitochondrial oxidative phosphorylation (mtOXPHOS) plays a significant role in AML tumorigenes...

    Authors: Wonhyoung Seo, Seungyeul Yoo, Yi Zhong, Sang-Hee Lee, Soo-Yeon Woo, Hee-Seon Choi, Minho Won, Taylor Roh, Sang Min Jeon, Kyeong Tae Kim, Prashanta Silwal, Min Joung Lee, Jun Young Heo, Nathan Lawlor, Sup Kim, Dongjun Lee…
    Citation: Journal of Hematology & Oncology 2022 15:156
    Content type: Correspondence Published on:

  2. CPX-351 (Europe: Vyxeos® liposomal; United States: Vyxeos®) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. In a phase 3 study in older adults with newly di...

    Authors: Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet and Thomas Prebet
    Citation: Journal of Hematology & Oncology 2022 15:155
    Content type: Brief Report Published on:

  3. Identifying T cell epitopes on pancreatic ductal adenocarcinoma (PDAC) associated antigens or neoantigens has been a challenge. In this study, we attempted to identify PDAC T cell epitopes by mass spectrometry...

    Authors: Kenji Fujiwara, Yingkuan Shao, Nan Niu, Tengyi Zhang, Brian Herbst, Mackenzie Henderson, Stephen Muth, Pingbo Zhang and Lei Zheng
    Citation: Journal of Hematology & Oncology 2022 15:154
    Content type: Correspondence Published on:

  4. Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory ro...

    Authors: Binghao Zhao, Huanzhang Li, Yu Xia, Yaning Wang, Yuekun Wang, Yixin Shi, Hao Xing, Tian Qu, Yu Wang and Wenbin Ma
    Citation: Journal of Hematology & Oncology 2022 15:153
    Content type: Review Published on:

  5. After decades of efforts, we have recently made progress into targeting KRAS mutations in several malignancies. Known as the ‘holy grail’ of targeted cancer therapies, KRAS is the most frequently mutated oncog...

    Authors: Kaushal Parikh, Giuseppe Banna, Stephen V. Liu, Alex Friedlaender, Aakash Desai, Vivek Subbiah and Alfredo Addeo
    Citation: Journal of Hematology & Oncology 2022 15:152
    Content type: Review Published on:

  7. Extramedullary multiple myeloma (EMD) is an aggressive subentity of multiple myeloma (MM) with poor prognosis. As more innovative therapeutic approaches are needed for the treatment of MM with EMD, we conducte...

    Authors: Ja Min Byun, Chang-Ki Min, Kihyun Kim, Soo-Mee Bang, Je-Jung Lee, Jin Seok Kim, Sung-Soo Yoon and Youngil Koh
    Citation: Journal of Hematology & Oncology 2022 15:150
    Content type: Research Published on:

  8. JX-594 is an oncolytic vaccinia virus genetically modified to replicate selectively in tumor cells. Metronomic chemotherapy has shown preclinical synergy with oncolytic viruses. We report here the results of t...

    Authors: Maud Toulmonde, Sophie Cousin, Michèle Kind, Jean-Philippe Guegan, Alban Bessede, Francois Le Loarer, Raul Perret, Coralie Cantarel, Carine Bellera and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2022 15:149
    Content type: Correspondence Published on:

  9. Acute promyelocytic leukemia (APL) has become curable over 95% patients under a complete chemo-free treatment with all-trans retinoic acid (ATRA) and arsenic trioxide in low-risk patients. Minimizing chemother...

    Authors: Ya-Fang Ma, Ying Lu, Qian Wu, Yin-Jun Lou, Min Yang, Jie-Yu Xu, Cai-Hong Sun, Li-Ping Mao, Gai-Xiang Xu, Li Li, Jian Huang, Huai-Yu Wang, Li-Jiang Lou, Hai-Tao Meng, Jie-Jing Qian, Wen-Juan Yu…
    Citation: Journal of Hematology & Oncology 2022 15:148
    Content type: Correspondence Published on:

  10. Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and maintaining genome stabi...

    Authors: Shuangying Li, Liangliang Wang, Yuanyuan Wang, Changyi Zhang, Zhenya Hong and Zhiqiang Han
    Citation: Journal of Hematology & Oncology 2022 15:147
    Content type: Review Published on:

  11. DNA lesions induced by alkylating agents are repaired by two canonical mechanisms, base excision repair dependent on poly(ADP) ribose polymerase 1 (PARP1) and the other mediated by O6-methylguanine (O6meG)-DNA m...

    Authors: Jodie D. Cropper, Dauren S. Alimbetov, Kevin T. G. Brown, Rostislav I. Likhotvorik, Andrew J. Robles, James T. Guerra, Boxue He, Yidong Chen, Youngho Kwon and Raushan T. Kurmasheva
    Citation: Journal of Hematology & Oncology 2022 15:146
    Content type: Correspondence Published on:

  12. Metastatic prostate cancer (PC) is a leading cause of cancer death in men worldwide. Targeting of the culprits of disease progression is an unmet need. Interleukin (IL)-30 promotes PC onset and development, bu...

    Authors: Carlo Sorrentino, Luigi D’Antonio, Stefania Livia Ciummo, Cristiano Fieni, Lorena Landuzzi, Francesca Ruzzi, Simone Vespa, Paola Lanuti, Lavinia Vittoria Lotti, Pier Luigi Lollini and Emma Di Carlo
    Citation: Journal of Hematology & Oncology 2022 15:145
    Content type: Research Published on:

  13. We assessed the mechanism by which multiple myeloma (MM) shapes the bone marrow (BM) microenvironment and affects MΦ polarization.

    Authors: Katia Beider, Valeria Voevoda-Dimenshtein, Ali Zoabi, Evgenia Rosenberg, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Lola Weiss, Michal Abraham, Amnon Peled and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2022 15:144
    Content type: Research Published on:

  14. The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs (excluding vaccines, cell-based therapies, and gene t...

    Authors: Qing Wu, Wei Qian, Xiaoli Sun and Shaojie Jiang
    Citation: Journal of Hematology & Oncology 2022 15:143
    Content type: Review Published on:

  15. Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy. Our previous study reported the potent antitumor activity of anti-TGF-...

    Authors: Ming Yi, Mengke Niu, Yuze Wu, Hong Ge, Dechao Jiao, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu and Kongming Wu
    Citation: Journal of Hematology & Oncology 2022 15:142
    Content type: Research Published on:

  16. Besides featured glucose consumption, recent studies reveal that cancer cells might prefer “addicting” specific energy substrates from the tumor microenvironment (TME); however, the underlying mechanisms remai...

    Authors: Tongyan Liu, Chencheng Han, Panqi Fang, Zhifei Ma, Xiaoxiao Wang, Hao Chen, Siwei Wang, Fanchen Meng, Cheng Wang, Erbao Zhang, Guozhang Dong, Hongyu Zhu, Wenda Yin, Jie Wang, Xianglin Zuo, Mantang Qiu…
    Citation: Journal of Hematology & Oncology 2022 15:141
    Content type: Research Published on:

  17. Pediatric cancers are the driving cause of death for children and adolescents. Due to safety requirements and considerations, treatment strategies and drugs for pediatric cancers have been so far scarcely stud...

    Authors: Hua Wang, Xiaowen Zhou, Chenbei Li, Shuxiang Yan, Chengyao Feng, Jieyu He, Zhihong Li and Chao Tu
    Citation: Journal of Hematology & Oncology 2022 15:140
    Content type: Review Published on:

  18. The booming of gene and cell therapy (GCT) worldwide in recent years has been observed, especially in the field of cancers. In order to provide the comprehensive GCT landscape in China with a focus on differen...

    Authors: Chen Yin, Jianchao Gao, Guanqiao Li, Hongxi Hu, Liyun Zhou, Shuang Lu and Xiaoyuan Chen
    Citation: Journal of Hematology & Oncology 2022 15:139
    Content type: Correspondence Published on:

  19. Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target fo...

    Authors: Aqu Alu, Hong Lei, Xuejiao Han, Yuquan Wei and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2022 15:138
    Content type: Review Published on:

  20. Circulating tumor DNA (ctDNA) has been proven as a marker for detecting minimal residual diseases following systemic therapies in mid-to-late-stage non-small-cell lung cancers (NSCLCs) by multiple studies. How...

    Authors: Siwei Wang, Ming Li, Jingyuan Zhang, Peng Xing, Min Wu, Fancheng Meng, Feng Jiang, Jie Wang, Hua Bao, Jianfeng Huang, Binhui Ren, Mingfeng Yu, Ninglei Qiu, Houhuai Li, Fangliang Yuan, Zhi Zhang…
    Citation: Journal of Hematology & Oncology 2022 15:137
    Content type: Correspondence Published on:

  21. Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. To provide specific, evi...

    Authors: Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin-Tai Yu, Yuan Li, Xiao-Qiu Li, Hong Chen, Dongxiao Zhuang, Jianyong Li, Bin Wang, Tao Jiang, Lanting Lyu…
    Citation: Journal of Hematology & Oncology 2022 15:136
    Content type: Review Published on:

  22. Transforming growth factor-β (TGF-β) signaling has a paradoxical role in cancer progression, and it acts as a tumor suppressor in the early stages but a tumor promoter in the late stages of cancer. Once cancer...

    Authors: Xueke Shi, Jin Yang, Shuzhi Deng, Hongdan Xu, Deyang Wu, Qingxiang Zeng, Shimeng Wang, Tao Hu, Fanglong Wu and Hongmei Zhou
    Citation: Journal of Hematology & Oncology 2022 15:135
    Content type: Review Published on:

  23. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with multiple roles in tumour growth, cell invasion and metastasis. We have previously established GSK-3 as an upstream regulator of PD-1 gene ex...

    Authors: Gary Shaw, Ludimila Cavalcante, Francis J. Giles and Alison Taylor
    Citation: Journal of Hematology & Oncology 2022 15:134
    Content type: Research Published on:

  24. Regulated cell death (RCD) is a critical and active process that is controlled by specific signal transduction pathways and can be regulated by genetic signals or drug interventions. Meanwhile, RCD is closely ...

    Authors: Rui Qin, Feng-Ming You, Qian Zhao, Xin Xie, Cheng Peng, Gu Zhan and Bo Han
    Citation: Journal of Hematology & Oncology 2022 15:133
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:151

  25. Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an ...

    Authors: Hailong Tian, Tingting Zhang, Siyuan Qin, Zhao Huang, Li Zhou, Jiayan Shi, Edouard C. Nice, Na Xie, Canhua Huang and Zhisen Shen
    Citation: Journal of Hematology & Oncology 2022 15:132
    Content type: Review Published on:

  26. Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), a...

    Authors: Mina Nikanjam, Shumei Kato and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2022 15:131
    Content type: Review Published on:

  29. circRNA has been established to play a pivotal role in tumorigenesis development in a variety of cancers; nevertheless, the biological functions and molecular mechanisms of hypoxia-induced exosomal circRNAs in...

    Authors: Jiewei Lin, Xinjing Wang, Shuyu Zhai, Minmin Shi, Chenghong Peng, Xiaxing Deng, Da Fu, Jiancheng Wang and Baiyong Shen
    Citation: Journal of Hematology & Oncology 2022 15:128
    Content type: Research Published on:

  30. Myeloid malignancies develop through the accumulation of genetic and epigenetic alterations that dysregulate hematopoietic stem cell (HSC) self-renewal, stimulate HSC proliferation and result in differentiatio...

    Authors: Edward A. Medina, Caroline R. Delma and Feng-Chun Yang
    Citation: Journal of Hematology & Oncology 2022 15:127
    Content type: Review Published on:

  31. The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first co...

    Authors: Desiree Kunadt, Sebastian Stasik, Klaus H. Metzeler, Christoph Röllig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, Alwin Krämer, Andreas Hochhaus, Sebastian Scholl, Inken Hilgendorf, Tim H. Brümmendorf, Edgar Jost…
    Citation: Journal of Hematology & Oncology 2022 15:126
    Content type: Research Published on:

  32. Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management of colorectal cancer (CRC) patients. Untargeted cfDNA analysis using whole-genome sequencing (WGS) does not need a prior...

    Authors: Ariane Hallermayr, Tobias Wohlfrom, Verena Steinke-Lange, Anna Benet-Pagès, Florentine Scharf, Ellen Heitzer, Ulrich Mansmann, Christopher Haberl, Maike de Wit, Holger Vogelsang, Markus Rentsch, Elke Holinski-Feder and Julia M. A. Pickl
    Citation: Journal of Hematology & Oncology 2022 15:125
    Content type: Research Published on:

  33. Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute ...

    Authors: Razan Mohty, Rama Al Hamed, Ali Bazarbachi, Eolia Brissot, Arnon Nagler, Amer Zeidan and Mohamad Mohty
    Citation: Journal of Hematology & Oncology 2022 15:124
    Content type: Review Published on:

  34. The vast majority of our knowledge regarding cancer radiobiology and the activation of radioresistance mechanisms emerged from studies using external beam radiation therapy (EBRT). Yet, less is known about the...

    Authors: Michal Grzmil, Paul Boersema, Ashish Sharma, Alain Blanc, Stefan Imobersteg, Martin Pruschy, Paola Picotti, Roger Schibli and Martin Behe
    Citation: Journal of Hematology & Oncology 2022 15:123
    Content type: Correspondence Published on:

  35. Circular RNAs (circRNAs) represent a novel type of regulatory RNA characterized by high evolutionary conservation and stability. CircRNAs are expected to be potential diagnostic biomarkers and therapeutic targ...

    Authors: Xiaolong Wang, Tong Chen, Chen Li, Wenhao Li, Xianyong Zhou, Yaming Li, Dan Luo, Ning Zhang, Bing Chen, Lijuan Wang, Wenjing Zhao, Shanji Fu and Qifeng Yang
    Citation: Journal of Hematology & Oncology 2022 15:122
    Content type: Research Published on:

  36. Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however...

    Authors: Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov and Yongheng Chen
    Citation: Journal of Hematology & Oncology 2022 15:121
    Content type: Review Published on:

  37. Metabolic reprogramming of cancer cells within the tumor microenvironment typically occurs in response to increased nutritional, translation and proliferative demands. Altered lipid metabolism is a marker of t...

    Authors: Yahui Zhu, Xingrong Lin, Xiaojun Zhou, Edward V. Prochownik, Fubing Wang and Youjun Li
    Citation: Journal of Hematology & Oncology 2022 15:120
    Content type: Review Published on:

  38. There is a paucity of information about molecularly driven therapy in osteosarcomas. We report a 31-year-old woman with chemotherapy–refractory metastatic osteosarcoma who was successfully treated with the com...

    Authors: Hanna E. Persha, Shumei Kato, Pradip De, Jacob J. Adashek, Jason K. Sicklick, Vivek Subbiah and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2022 15:119
    Content type: Correspondence Published on:

  39. Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolu...

    Authors: Yi Wang, Kai Conrad Cecil Johnson, Margaret E. Gatti-Mays and Zihai Li
    Citation: Journal of Hematology & Oncology 2022 15:118
    Content type: Review Published on:

  40. A cardinal feature that distinguishes clinically high-risk neuroblastoma from low-risk tumors is telomere maintenance. Specifically, neuroblastoma tumors with either active telomerase or alternative lengthenin...

    Authors: Eun Young Yu, Nai-Kong V. Cheung and Neal F. Lue
    Citation: Journal of Hematology & Oncology 2022 15:117
    Content type: Review Published on:

  41. Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disea...

    Authors: Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic, Nina Rajovic, David Allsup, Alejandro Alonso Cabrero, Martin Andres, Monica Baile Gonzales, Antonella Capasso, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Juan Gonzalo Correa, Lorenzo De Paoli…
    Citation: Journal of Hematology & Oncology 2022 15:116
    Content type: Research Published on:

  42. Patients with follicular lymphoma (FL) who experience disease progression within 24 months (POD24) have inferior outcomes. The tumor immune microenvironment (TIME) plays a crucial role in pathogenesis and prog...

    Authors: Long Liu, Xingxing Yu, Zhifeng Li, Xiaohua He, Jie Zha, Zhijuan Lin, Yan Hong, Huijian Zheng, Qian Lai, Kaiyang Ding, Xian Jia, Guo Fu, Haifeng Yu, Haiyan Yang, Zhiming Li, Ken H. Young…
    Citation: Journal of Hematology & Oncology 2022 15:115
    Content type: Correspondence Published on:

  43. Lung adenocarcinoma (LUAD) is the leading cause of death worldwide. However, the roles of long noncoding RNAs (lncRNAs) hijacked by super-enhancers (SEs), vital regulatory elements of the epigenome, remain elu...

    Authors: Te Zhang, Wenjie Xia, Xuming Song, Qixing Mao, Xing Huang, Bing Chen, Yingkuan Liang, Hui Wang, Yuzhong Chen, Xinnian Yu, Zeyu Zhang, Wenmin Yang, Lin Xu, Gaochao Dong and Feng Jiang
    Citation: Journal of Hematology & Oncology 2022 15:114
    Content type: Research Published on:

  44. BCR-ABL1T315I mutations confer resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new potent BCR-ABL1 TKI with preclinical activity against T315I-mutated CML. I...

    Authors: Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu, Bingcheng Liu, Yanli Zhang, Li Meng, Huanling Zhu, Xin Du, Suning Chen, Yang Liang, Yu Hu, Xiaoli Liu, Yongping Song, Lichuang Men…
    Citation: Journal of Hematology & Oncology 2022 15:113
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:13

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:159

  45. Although a substantial increase in the survival of patients with other cancers has been observed in recent decades, pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest diseases. No effective s...

    Authors: Zengyu Feng, Kexian Li, Kai Qin, Juyong Liang, Minmin Shi, Yang Ma, Shiwei Zhao, Huaiyu Liang, Dongni Han, Baiyong Shen, Chenghong Peng, Hao Chen and Lingxi Jiang
    Citation: Journal of Hematology & Oncology 2022 15:112
    Content type: Research Published on:

  46. The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of checkpoint molecules: anti-programmed c...

    Authors: Yuchen Wang, Hao Zhang, Chao Liu, Zeyu Wang, Wantao Wu, Nan Zhang, Longbo Zhang, Jason Hu, Peng Luo, Jian Zhang, Zaoqu Liu, Yun Peng, Zhixiong Liu, Lanhua Tang and Quan Cheng
    Citation: Journal of Hematology & Oncology 2022 15:111
    Content type: Review Published on:

  47. Emerging evidence indicates that the detection and clearance of cancer cells via phagocytosis induced by innate immune checkpoints play significant roles in tumor-mediated immune escape. The most well-describe...

    Authors: Wei Li, Fang Wang, Rongqun Guo, Zhilei Bian and Yongping Song
    Citation: Journal of Hematology & Oncology 2022 15:110
    Content type: Review Published on:

  48. Multiple Myeloma (MM) is a progressive plasma cell neoplasm characterized by heterogeneous clonal expansion. Despite promising response rates achieved with anti-BCMA CAR-T cell therapy, patients may still rela...

    Authors: Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Christos Adamopoulos, Mark M. Stevens, Katerina Kappes, Violetta Leshchenko, Daniel Verina, Sundar Jagannath, Poulikos I. Poulikakos, Samir Parekh and Alessandro Laganà
    Citation: Journal of Hematology & Oncology 2022 15:109
    Content type: Case Report Published on:

  49. The pathophysiology of COVID-19-associated coagulopathy is complex and not fully understood. SARS-CoV-2 spike protein (SP) may activate platelets and interact with fibrin(ogen). We aimed to investigate whether...

    Authors: Manuela De Michele, Giulia d’Amati, Martina Leopizzi, Marta Iacobucci, Irene Berto, Svetlana Lorenzano, Laura Mazzuti, Ombretta Turriziani, Oscar G. Schiavo and Danilo Toni
    Citation: Journal of Hematology & Oncology 2022 15:108
    Content type: Correspondence Published on:

  50. Multiple myeloma (MM) and its precursors monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) are 2–3 times more common in African Americans (AA) than European Americans (EA)....

    Authors: Brian C.-H. Chiu, Zhou Zhang, Benjamin A. Derman, Jason Karpus, Liangzhi Luo, Sheng Zhang, Spencer S. Langerman, Madina Sukhanova, Parveen Bhatti, Andrzej Jakubowiak, Chuan He and Wei Zhang
    Citation: Journal of Hematology & Oncology 2022 15:106
    Content type: Correspondence Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us